Correction to: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)

doi:10.1093/ecco-jcc/jjag090

Correction to: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)

Journal: Journal of Crohn's & colitis (Q1)
Published: 7 July 2026
Study design: Narrative review / expert opinion
Evidence level: Level 1, High (CEBM 1b)
PMID: 42455704
DOI: 10.1093/ecco-jcc/jjag090

Why clinicians should know about it

Picked for Gastroenterology (paper of the day, 16 July 2026): Recent Gastroenterology research from a high-quartile journal.
Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (paper of the day, 16 July 2026).

View on PubMed Full text at the publisher Open in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.